Improved treatment for diabetes type 2 associated heart failure
Respected Editor, Heart failure is when the heart muscle becomes stiff, weakened or enlarged, which makes it unable to pump blood effectively throughout the body. This can lead to a fluid buildup in the body, shortness of breath, fatigue, and other symptoms. Heart failure (HF) has many causative fa...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pakistan Medical Association
2023-06-01
|
| Series: | Journal of the Pakistan Medical Association |
| Online Access: | https://ojs.jpma.org.pk/index.php/public_html/article/view/8085 |
| _version_ | 1797740785229103104 |
|---|---|
| author | Muhammad Usman Alamgir |
| author_facet | Muhammad Usman Alamgir |
| author_sort | Muhammad Usman Alamgir |
| collection | DOAJ |
| description |
Respected Editor, Heart failure is when the heart muscle becomes stiff, weakened or enlarged, which makes it unable to pump blood effectively throughout the body. This can lead to a fluid buildup in the body, shortness of breath, fatigue, and other symptoms. Heart failure (HF) has many causative factors. However, the rising incidence and mortality rates of diabetes associated with heart failure have transformed it into a significant public health issue in Pakistan. Based on estimates from the International Diabetes Federation in a 2022 study, Pakistan has the highest comparative prevalence of diabetes, reaching 30% in 2021. It is projected to exceed 33% by 2045, maintaining its position at the top. When ranked by the number of adults with diabetes, Pakistan ranks third in 2021 and is predicted to retain this position in 2045. China and India hold the first and second positions,respectively.1 Diabetes prevalence in adults almost doubled between 1980 and 2014 worldwide.2 While there exist various risk factors such as hypertension, renal dysfunction, coronary artery disease, heart valve problems, cardiomyopathy, and obesity, among others, for HF. Diabetes mellitus was independently associated with an 80% increased risk of HF.3 The standard treatment as per the study published in 2001 treatment for congestive HF is therapy with ACE inhibitors, Beta-blockers, and diuretics. Digoxin for patients with atrial fibrillation. Aldosterone antagonists recommended in patients with stable New York Heart Association class III or IV HF. If ACE inhibitors are not tolerated, angiotensin receptor blockers, hydralazine and isosorbide are recommended.4 There have been clinical trials in people with diabetes to see if diabetes drugs can also treat and/or reduce the risk of cardiovascular disease. In clinical trials, a type of diabetes drug, sodium-glucose cotransporter-2 inhibitors (SGLT-2is, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin), has helped people with both diabetes and cardiovascular disease.5 Considering the rising risk of diabetes associated with heart failure in Pakistan, physicians should encourage the use of SGLT2 inhibitors like dapagliflozin and empagliflozin. Furthermore, doctors will be able to manage the disease and prevent it from reaching its final stages more effectively if improved screening techniques for diabetes are introduced and implemented; such as widespread access to blood glucose testing, utilizing risk assessment tools such as questionnaires or predictive algorithms can identify individuals who are at a higher risk of developing diabetes and target them for testing. Moreover, making lifestyle modifications such as quitting smoking and limiting alcohol consumption.
Continue...
|
| first_indexed | 2024-03-12T14:17:24Z |
| format | Article |
| id | doaj.art-534279c9b7334418993189c5faec4576 |
| institution | Directory Open Access Journal |
| issn | 0030-9982 |
| language | English |
| last_indexed | 2024-03-12T14:17:24Z |
| publishDate | 2023-06-01 |
| publisher | Pakistan Medical Association |
| record_format | Article |
| series | Journal of the Pakistan Medical Association |
| spelling | doaj.art-534279c9b7334418993189c5faec45762023-08-20T04:48:01ZengPakistan Medical AssociationJournal of the Pakistan Medical Association0030-99822023-06-0173910.47391/JPMA.8085Improved treatment for diabetes type 2 associated heart failureMuhammad Usman Alamgir01st Year MBBS Student, Ziauddin Medical College, Karachi, Pakistan Respected Editor, Heart failure is when the heart muscle becomes stiff, weakened or enlarged, which makes it unable to pump blood effectively throughout the body. This can lead to a fluid buildup in the body, shortness of breath, fatigue, and other symptoms. Heart failure (HF) has many causative factors. However, the rising incidence and mortality rates of diabetes associated with heart failure have transformed it into a significant public health issue in Pakistan. Based on estimates from the International Diabetes Federation in a 2022 study, Pakistan has the highest comparative prevalence of diabetes, reaching 30% in 2021. It is projected to exceed 33% by 2045, maintaining its position at the top. When ranked by the number of adults with diabetes, Pakistan ranks third in 2021 and is predicted to retain this position in 2045. China and India hold the first and second positions,respectively.1 Diabetes prevalence in adults almost doubled between 1980 and 2014 worldwide.2 While there exist various risk factors such as hypertension, renal dysfunction, coronary artery disease, heart valve problems, cardiomyopathy, and obesity, among others, for HF. Diabetes mellitus was independently associated with an 80% increased risk of HF.3 The standard treatment as per the study published in 2001 treatment for congestive HF is therapy with ACE inhibitors, Beta-blockers, and diuretics. Digoxin for patients with atrial fibrillation. Aldosterone antagonists recommended in patients with stable New York Heart Association class III or IV HF. If ACE inhibitors are not tolerated, angiotensin receptor blockers, hydralazine and isosorbide are recommended.4 There have been clinical trials in people with diabetes to see if diabetes drugs can also treat and/or reduce the risk of cardiovascular disease. In clinical trials, a type of diabetes drug, sodium-glucose cotransporter-2 inhibitors (SGLT-2is, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin), has helped people with both diabetes and cardiovascular disease.5 Considering the rising risk of diabetes associated with heart failure in Pakistan, physicians should encourage the use of SGLT2 inhibitors like dapagliflozin and empagliflozin. Furthermore, doctors will be able to manage the disease and prevent it from reaching its final stages more effectively if improved screening techniques for diabetes are introduced and implemented; such as widespread access to blood glucose testing, utilizing risk assessment tools such as questionnaires or predictive algorithms can identify individuals who are at a higher risk of developing diabetes and target them for testing. Moreover, making lifestyle modifications such as quitting smoking and limiting alcohol consumption. Continue... https://ojs.jpma.org.pk/index.php/public_html/article/view/8085 |
| spellingShingle | Muhammad Usman Alamgir Improved treatment for diabetes type 2 associated heart failure Journal of the Pakistan Medical Association |
| title | Improved treatment for diabetes type 2 associated heart failure |
| title_full | Improved treatment for diabetes type 2 associated heart failure |
| title_fullStr | Improved treatment for diabetes type 2 associated heart failure |
| title_full_unstemmed | Improved treatment for diabetes type 2 associated heart failure |
| title_short | Improved treatment for diabetes type 2 associated heart failure |
| title_sort | improved treatment for diabetes type 2 associated heart failure |
| url | https://ojs.jpma.org.pk/index.php/public_html/article/view/8085 |
| work_keys_str_mv | AT muhammadusmanalamgir improvedtreatmentfordiabetestype2associatedheartfailure |